Taurolidine/Citrate Lock Therapy for Primary Prevention of Catheter-Related Infections in Cancer Patients: Results of a Prospective, Randomized, Phase IV Trial (ATAPAC).

Date publication

mai 2017

Journal

Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GOETZ Christophe , Dr LONGO Raffaele , Dr QUETIN Philippe

Tous les auteurs :
Longo R, Llorens M, Goetz C, Platini C, Eid N, Sellies J, Ouamara N, Quétin P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28463827

Résumé

Totally implantable venous access port (TIVAP)-related infections (RIs) remain a serious health problem in cancer patients receiving an intravenous (i.v.) therapy.

Mots clés

Catheter, Infection, Taurolidine, Totally implantable venous access port

Référence

Oncology. 2017 May;: